Traders Purchase Large Volume of Call Options on Rezolute (NASDAQ:RZLT)

Rezolute, Inc. (NASDAQ:RZLT) was the target of some unusual options trading on Monday. Stock traders acquired 4,099 call options on the stock. This represents an increase of approximately 618% compared to the average volume of 571 call options.

Rezolute Stock Down 0.2%

Shares of RZLT opened at $4.32 on Wednesday. Rezolute has a 52-week low of $1.07 and a 52-week high of $11.46. The company has a market capitalization of $417.83 million, a PE ratio of -5.68 and a beta of 0.53. The stock has a fifty day simple moving average of $4.47 and a two-hundred day simple moving average of $4.09.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings results on Thursday, September 24th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.05). As a group, equities analysts anticipate that Rezolute will post -0.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Rezolute

Several institutional investors and hedge funds have recently bought and sold shares of the company. AlphaCentric Advisors LLC lifted its stake in shares of Rezolute by 6.2% in the 1st quarter. AlphaCentric Advisors LLC now owns 71,227 shares of the company’s stock valued at $217,000 after purchasing an additional 4,171 shares during the last quarter. Auxano Advisors LLC acquired a new stake in shares of Rezolute during the 2nd quarter worth about $52,000. Sequoia Financial Advisors LLC purchased a new stake in Rezolute in the 2nd quarter valued at about $75,000. WINTON GROUP Ltd acquired a new position in Rezolute in the second quarter valued at about $88,000. Finally, ADAR1 Capital Management LLC lifted its position in Rezolute by 51.7% in the first quarter. ADAR1 Capital Management LLC now owns 58,679 shares of the company’s stock valued at $179,000 after buying an additional 20,000 shares during the last quarter. 82.97% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Rezolute

Here are the key news stories impacting Rezolute this week:

• Positive Sentiment: The FDA recommended a pre-BLA meeting, an important regulatory step that could help Rezolute prepare a potential biologics license application for ersodetug. The agency also reiterated its commitment to addressing the significant unmet need in hyperinsulinism. The meeting does not guarantee approval, but it indicates that discussions toward a possible filing can continue. Rezolute FDA pre-BLA announcement
• Positive Sentiment: Cantor Fitzgerald upgraded RZLT to “Overweight” from “Neutral,” citing the pre-BLA meeting opportunity for ersodetug. Cantor Fitzgerald upgrades Rezolute
• Positive Sentiment: Citizens JMP raised its price target from $11 to $15 and assigned a “Market Outperform” rating, implying substantial upside from the referenced $4.32 share price. Rezolute stock price expected to rise
• Neutral Sentiment: Call-option activity surged, with investors purchasing 4,099 calls—about 618% above average volume—signaling speculative bullish interest but not a fundamental business change.
• Negative Sentiment: Rezolute still faces clinical and regulatory risk following a Phase 3 trial miss. A pre-BLA meeting is not an approval or a guarantee that the FDA will accept a future BLA, making additional data and regulatory discussions critical.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. HSBC raised Rezolute to a “buy” rating in a research note on Friday, September 25th. Zacks Research upgraded shares of Rezolute from a “strong sell” rating to a “hold” rating in a research report on Friday, August 14th. HC Wainwright raised their price target on shares of Rezolute from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, September 25th. Wall Street Zen lowered shares of Rezolute from a “hold” rating to a “sell” rating in a research report on Tuesday, June 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rezolute in a research note on Friday, July 17th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Rezolute currently has an average rating of “Moderate Buy” and an average target price of $11.22.

Rezolute Company Profile

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. The company’s research is centered on conditions involving abnormal insulin signaling and glucose regulation, including rare disorders and complications associated with diabetes.

Rezolute’s lead investigational product is RZ358, a human monoclonal antibody designed to reduce the effects of excessive insulin activity. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas releases too much insulin and causes potentially dangerous episodes of low blood sugar.